Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis®)


BERLIN, Conn., Aug. 5, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Apixaban Tablets (generic for Eliquis®). This product was developed by Towa Pharmaceutical Europe, S.L. in its manufacturing facility located in Martorelles, Spain. According to industry sales data, Eliquis generated annual sales of $14 billion during the twelve months ending May 2021. Breckenridge has been granted a license under confidential terms permitting Breckenridge to launch generic Apixaban Tablets under its Abbreviated New Drug Application at a later date.

About Breckenridge:
Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.
www.bpirx.com

For further information, please contact:
Breckenridge Pharmaceutical, Inc.
Robert Gasparino, Associate Vice President ? Business Development
Tel: 860-828-8140
E-mail: rgasparino@bpirx.com

*All brand names and trademarks are the property of their respective owners.

SOURCE Breckenridge Pharmaceutical, Inc.


These press releases may also interest you

at 20:00
Helix BioPharma Corp. ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial...

at 19:59
The Centers for Medicare and Medicaid Services (CMS) released its annual quality rankings. For the 2022 plan year, Network Health earned a 5 out of 5-Star Rating from CMS for its Medicare Advantage PPO plans. This is Medicare's highest possible...

at 19:21
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Cyltezo® (adalimumab-adbm) as the first Interchangeable biosimilar with Humira® (adalimumab). The FDA...

at 19:20
Novartis Pharmaceuticals Canada Inc. applauds the government of Quebec's decision to provide public reimbursement for Zolgensma® (onasemnogene abeparvovec)...

at 18:20
Worcester Polytechnic Institute (WPI) researcher Loris Fichera has developed a flexible, slimmed-down robotic laser probe for endoscopic larynx surgeries that could reduce recovery time for patients and cut health care spending by shifting procedures...

at 18:15
The "Global Industrial Radiography Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technique (Film-based Radiography and Digital Radiography); End-User Industry" report has been added to ResearchAndMarkets.com's offering. The...



News published on 5 august 2021 at 13:26 and distributed by: